Media Summary: Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses the ... Sarah Holstein, MD, PhD, University of Nebraska There are currently no concrete guidelines for how to
Mrd Evaluation In Clinical Practice For Mm - Detailed Analysis & Overview
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses the ... Sarah Holstein, MD, PhD, University of Nebraska There are currently no concrete guidelines for how to Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the importance of using measurable residual ... Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, discusses the Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the impact of new minimal residual disease ...
Jill Corre, PharmD, PhD, of L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, ... Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and results ... Mohamad Mohty, MD, PhD, University Pierre & Marie Curie, Paris, France, Elena Zamagni, MD, PhD, University of Bologna, ... For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and ... Learn more about Minimal Residual Disease ( Prof Fengyan Jin of Jilin University, Jilin, China, outlines the issues with current criteria regarding (measurable residual disease) ...
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, shares the main findings of his recent ... Here, Robin Foà, MD, from Sapienza University of Rome, Rome, Italy, talks about the challenges in In this video, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, discusses the ongoing
